Recent News

• 12.02.2025 - FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
• 11.10.2025 - FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.03.2025 - FibroGen to Report Third Quarter 2025 Financial Results
• 09.24.2025 - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
• 09.24.2025 - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
• 09.24.2025 - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
• 09.02.2025 - FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Recent Filings

• 11.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - EX-99.1 EX-99.1
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.10.2025 - 8-K Current report
• 11.06.2025 - 8-K Current report
• 09.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.05.2025 - EX-99.1 EX-99.1
• 09.05.2025 - 8-K Current report